Australia is eagerly awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://mohamadefkh634691.wiki-jp.com/2537726/novo_nordisk_s_retatrutide_australia_a_promising_breakthrough_for_obesity_treatment